Exercise for Patients With Renal Cell Cancer Receiving Sunitinib

Charite University, Berlin, Germany70 enrolled

Overview

In this randomized, controlled trial the investigators evaluate the effects of an exercise program lasting for 12 weeks on the physical performance, the cardiovascular function (24h blood pressure, rest blood pressure and hear function) and the fatigue and mood of patients with renal cell carcinoma undergoing a therapy with Sunitinib.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

SUPPORTIVE_CARE

Masking

SINGLE

Enrollment

Conditions

Renal Cell Carcinoma

Interventions

Endurance exerciseOTHER

Endurance exercise, 3 times weekly for 35-45 minutes, 12 weeks.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * 18 to 75 years * Understanding of written German * Treatment with Sunitinib * Ability to walk Exclusion Criteria: * Cardiovascular, pulmonary or osteoarticular disease which can be aggravated by exercise * BMI \< 18 or \> 30

Locations (1)

Section Sports Medicine, Charité Universitätsmedizin Berlin, Hindenburgdamm 30

Berlin, State of Berlin, Germany

RECRUITING

Outcomes

Primary Outcomes

Fatigue

Time frame: 12 weeks

Secondary Outcomes

VO2max

Time frame: 12 weeks

Systolic and diastolic blood pressure (24 h)

Time frame: 12 weeks

Depression score

Time frame: 12 weeks

Central Contacts

Fernando C. Dimeo, MD

CONTACT

+493084452098 fernando.dimeo@charite.de

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.